Search research articles
Contact Us
Filters
Showing results (71-80 of 80) with videos related to
Page
of 8
Sort By:
You have reached the last page of results.
This site can display upto 80 results.
JCO Precision Oncology
|
February 6, 2025
Phase II Study of Copanlisib in Patients With PTEN Loss: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols Z1G and Z1H
Mohamed A Gouda, Zihan Wei, Jordi Rodon, et al.
JCO Precision Oncology
|
October 30, 2025
Germline Cancer Predisposition Results From the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial
Sarah Scollon, Sharon E Plon, Steven Joffe, et al.
Nature Medicine
|
June 15, 2023
The NCI-MATCH trial: lessons for precision oncology
Peter J O'Dwyer, Robert J Gray, Keith T Flaherty, et al.
JCO Precision Oncology
|
October 9, 2025
Phase II Study of Vismodegib in Patients With <i>SMO-</i> or <i>PTCH1</i>-Mutated Tumors: Results From the National Cancer Institute Molecular Analysis for Therapy Choice Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Trial (EAY131) Subprotocol T
Anne S Tsao, Zihe Song, Alan L Ho, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 20, 2026
Crizotinib in Patients with Tumors with MET Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2
Niamh Coleman, Zihan Wei, A John Iafrate, et al.
JCO Precision Oncology
|
June 17, 2026
Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subprotocol Z1I
Shivaani Kummar, Zihe Song, Kim A Reiss, et al.
Journal of the National Cancer Institute
|
April 28, 2020
The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study
Barbara A Conley, Lou Staudt, Naoko Takebe, et al.
Journal of the National Cancer Institute
|
January 11, 2020
The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design
Keith T Flaherty, Robert Gray, Alice Chen, et al.
Cancer Cell
|
November 20, 2020
Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment
David A Wheeler, Naoko Takebe, Toshinori Hinoue, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 4, 2025
A Concordance Study among 26 NGS Laboratories Participating in the NCI Molecular Analysis for Therapy Choice Clinical Trial
Linda K Zane, Laura M Yee, Ting-Chia Chang, et al.
Page
of 8
Search research articles
Search
Showing results (71-80 of 80) with videos related to
Sort By:
Page
of 8
You have reached the last page of results.
This site can display upto 80 results.
JCO Precision Oncology
|
February 6, 2025
Phase II Study of Copanlisib in Patients With PTEN Loss: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols Z1G and Z1H
Mohamed A Gouda, Zihan Wei, Jordi Rodon, et al.
JCO Precision Oncology
|
October 30, 2025
Germline Cancer Predisposition Results From the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial
Sarah Scollon, Sharon E Plon, Steven Joffe, et al.
Nature Medicine
|
June 15, 2023
The NCI-MATCH trial: lessons for precision oncology
Peter J O'Dwyer, Robert J Gray, Keith T Flaherty, et al.
JCO Precision Oncology
|
October 9, 2025
Phase II Study of Vismodegib in Patients With <i>SMO-</i> or <i>PTCH1</i>-Mutated Tumors: Results From the National Cancer Institute Molecular Analysis for Therapy Choice Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Trial (EAY131) Subprotocol T
Anne S Tsao, Zihe Song, Alan L Ho, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 20, 2026
Crizotinib in Patients with Tumors with MET Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2
Niamh Coleman, Zihan Wei, A John Iafrate, et al.
JCO Precision Oncology
|
June 17, 2026
Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subprotocol Z1I
Shivaani Kummar, Zihe Song, Kim A Reiss, et al.
Journal of the National Cancer Institute
|
April 28, 2020
The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study
Barbara A Conley, Lou Staudt, Naoko Takebe, et al.
Journal of the National Cancer Institute
|
January 11, 2020
The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design
Keith T Flaherty, Robert Gray, Alice Chen, et al.
Cancer Cell
|
November 20, 2020
Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment
David A Wheeler, Naoko Takebe, Toshinori Hinoue, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 4, 2025
A Concordance Study among 26 NGS Laboratories Participating in the NCI Molecular Analysis for Therapy Choice Clinical Trial
Linda K Zane, Laura M Yee, Ting-Chia Chang, et al.
Page
of 8